Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F40C8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,229
Award facts
- Contract value 100% obligated
- $19,229.17 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $19,229.17 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on February 4, 2026, with completion targeted for February 5, 2026. This firm fixed-price, non-set-aside contract represents a small-value transaction within the company's broader federal pharmaceutical supply portfolio. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems.
This delivery order is executed under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 31, 2031. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling Cencora/AmerisourceBergen to supply an extensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, and vaccines to support military healthcare programs worldwide. Dupixent is a biologic immunosuppressant medication commonly used to treat conditions such as atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis, making this delivery order consistent with the company's role in supplying specialized therapeutic medications to government healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F40C8?
SPE2DR26F40C8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26F40C8 worth?
The government has obligated $19,229 on SPE2DR26F40C8.
Is contract SPE2DR26F40C8 an order under another contract?
Yes. SPE2DR26F40C8 is a delivery order under SPE2DR25D1051, an indefinite delivery contract.
Was contract SPE2DR26F40C8 competed?
The extent of competition for SPE2DR26F40C8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award